✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Larazotide is an investigational drug.
There have been 9 clinical trials for Larazotide. The most recent clinical trial was a Phase 2 trial, which was initiated on May 29th 2019.
The most common disease conditions in clinical trials are Celiac Disease, Syndrome, and COVID-19. The leading clinical trial sponsors are 9 Meters Biopharma, Inc., Alba Therapeutics, and Teva Pharmaceuticals USA.
There are two US patents protecting this investigational drug and thirty-six international patents.
Recent Clinical Trials for Larazotide
|AT1001 for the Treatment of COVID-19 Related MIS-C||Massachusetts General Hospital||Phase 2|
|Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms||9 Meters Biopharma, Inc.||Phase 3|
|Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms||Innovate Biopharmaceuticals||Phase 3|
Top disease conditions for Larazotide
Top clinical trial sponsors for Larazotide
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Larazotide||See Plans and Pricing||Gluten-related disorders||H.J. Heinz Company Brands LLC (Pittsburgh, PA)||See Plans and Pricing|
|Larazotide||See Plans and Pricing||Larazotide acetate compositions||Alba Therapeutics Corporation (Baltimore, MD)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Larazotide||Australia||AU2013277316||2032-06-18||See Plans and Pricing|
|Larazotide||Australia||AU2018203543||2032-06-18||See Plans and Pricing|
|Larazotide||Brazil||BR112014031666||2032-06-18||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|